Table 2.

Patient characteristics in randomized trials of beta blockers for the prevention of sudden cardiac death

Trial (Reference)	Mean age (Years)	Male (%)	Inclusion criteria	Population (Ischaemic or non-ischaemic)	Mean EF (%)	NYHA
Anderson et al.	50	66	IDC	Non-ischaemic	29	II-IV
ANZ13	67	80	chronic heart failure	Ischaemic	29	II-III
BEST6	60	78	NYHA III-IV, EF ≤ 35%	Both	23	III-IV
BHAT	55	NR	MI, HF	NR	NR	NR
Bristow et al.14	55	61	IDC and ISCD	Both	24	I-IV
Bristow et al.15	60	76	Mild, moderate, chronic heart failure	Both	23	II-IV
CAPRICORN16	63	74	Acute MI, EF ≤ 40%	Ischaemic	32	NR
CELICARD	57	89.5	NYHA II- IV, LVEF<40%	Both	26	II-III
CIBIS II18	61	80	NYHA III or IV, EF ≤ 35%	Both	28	III-IV
CIBIS17	60	83	IDC, NYHA III-IV, ≤ 40%	Both	25	III-IV
Colucci et al.19	54	85	Mildly symptomatic heart failure	Both	23	II-III
COPERNICUS20	63.3	79.5	HF and EF ≤ 25%	67% ischaemic	20	NR
de Milliano et al.	65	60	HF,, LVEF<35%,	Both	25	II-III
ELANDD	66	35	HF, age>40 years, LVEF>45%	Non-ischaemic	62	II-III
Engleimeir et al.21	50	64	IDC	Both	17	II-III
Fisher et al22	63	96	HF and CAD	NR	23	II-IV
Hansteen V. et al.23	58	84.5	Acute MI	NR	NR	NR
Krum et al.24	55	78	Advanced heart failure	Both	16	II-IV
MDC25	49	73	DCM and EF<40%	Non-ischaemic	22	I-III
MERIT-HF26	64	77	NYHA II-IV,EF ≤ 40%	Both	28	II-IV
Metra et al.27	51	90	NYHA II-III, IDC	Non-ischaemic	20	II-III
Olsen et al.28	52	94	NYHA II-III, IDC/CAD	Both	20	II-IV
Packer et al.29	58	77	Chronic heart failure	Both	23	II-IV

CAD Coronary artery disease, CHF congestive heart failure, DCM dilated cardiomyopathy, ISCD ischemic dilated cardiomyopathy, EF ejection fraction, HF Heart failure, IDC ischemic dilated cardiomyopathy, MDC Metoprolol in Dilated Cardiomyopathy, MI myocardial infarction, NR not reported, NYHA 'Classification of' New York Heart Association.